Levent Elmas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Levent Elmas has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
- Yavuz Dodurga
Department of Medical Biology, Pamukkale University, Denizli, Turkey
11 shared publications Mücahit Seçme
Department of Medical Biology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
5 shared publications- Mücahit Seçme
Department of Medical Biology, Faculty of Medicine, Ordu University, Ordu, Türkiye
5 shared publications - Cigir Biray Avci
Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey
4 shared publications Vildan Caner
University of Pamukkale, Faculty of Medicine, Department of Medical Biology, Denizli, Turkey
3 shared publications- Volkan Tekin
Department of Physiology, Gülhane Faculty of Medicine, University of Health Sciences, Ankara, Türkiye
3 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by The European Research Journal in The European Research Journal
- p. 1447-1457
Sequential Mitochondrial Transplantation Abrogates Agmatine-Mediated Neuroprotection Against 6-OHDA Toxicity in SH-SY5Y Cells
Objective: Parkinson disease (PD) involves dopaminergic neuron loss from mitochondrial dysfunction and oxidative stress. We investigated the combined, sequential effects of mesenchymal stem cell–derived mitochondrial transplantation (MitoTr) and pharmacological agmatine modulation in a PD–like undifferentiated SH-SY5Y cellular model. Methods: Undifferentiated SH-SY5Y cells were exposed to 6-hydroxydopamine (6-OHDA; 350 μM) for 24 hours and sequentially treated with mitochondria (5 or 10 μg/mL) and agmatine (100 μM; 2 hours post-MitoTr). Cell viability was assessed via MTT assays (n = 8 independent experiments). Total-lysate cytochrome c ELISA (n = 3) and Western blots for DJ-1, REDD1, and α-synuclein (n = 4) were performed across 4 core groups. Results: 6-OHDA significantly reduced viability compared with Control (mean [SEM], 0.50 [0.05] vs 1.00 [0.04]; P < .001); postinjury agmatine restored it to near-control levels (mean [SEM], 0.97 [0.20]; P < .001\) vs 6-OHDA), while agmatine alone had no effect (P > .99). Conversely, MitoTr-containing groups showed significantly lower viability than Control, Agmatine, and Agmatine + 6-OHDA groups (P < .001). Most MitoTr arms fell significantly below 6-OHDA alone (P < .05), except the 5 μg/mL triple group (P = .13). Expression of DJ-1, REDD1, and α-synuclein decreased numerically relative to Control without statistical significance (P > .05). Total-lysate cytochrome c was significantly elevated only in the triple-combination group compared with the Control group (mean [SEM], 36.01 [3.65] versus 22.63 [1.08] ng/mL; P = .03). Conclusions: Postinjury agmatine rescued 6-OHDA-induced viability loss, but sequential MitoTr followed by agmatine caused an additional marked reduction in viability rather than synergistic neuroprotection. Molecular alterations remained exploratory and nonsignificant. This MitoTr-associated loss may reflect antiproliferative effects in neuroblastoma-derived cells, underscoring the need for optimized protocols and nonmalignant models.
- 1 December 2026
- Published by The European Research Journal in The European Research Journal
- p. 1447-1457
Open AccessSequential Mitochondrial Transplantation Abrogates Agmatine-Mediated Neuroprotection Against 6-OHDA Toxicity in SH-SY5Y Cells
Objective: Parkinson disease (PD) involves dopaminergic neuron loss from mitochondrial dysfunction and oxidative stress. We investigated the combined, sequential effects of mesenchymal stem cell–derived mitochondrial transplantation (MitoTr) and pharmacological agmatine modulation in a PD–like undifferentiated SH-SY5Y cellular model. Methods: Undifferentiated SH-SY5Y cells were exposed to 6-hydroxydopamine (6-OHDA; 350 μM) for 24 hours and sequentially treated with mitochondria (5 or 10 μg/mL) and agmatine (100 μM; 2 hours post-MitoTr). Cell viability was assessed via MTT assays (n = 8 independent experiments). Total-lysate cytochrome c ELISA (n = 3) and Western blots for DJ-1, REDD1, and α-synuclein (n = 4) were performed across 4 core groups. Results: 6-OHDA significantly reduced viability compared with Control (mean [SEM], 0.50 [0.05] vs 1.00 [0.04]; P < .001); postinjury agmatine restored it to near-control levels (mean [SEM], 0.97 [0.20]; P < .001\) vs 6-OHDA), while agmatine alone had no effect (P > .99). Conversely, MitoTr-containing groups showed significantly lower viability than Control, Agmatine, and Agmatine + 6-OHDA groups (P < .001). Most MitoTr arms fell significantly below 6-OHDA alone (P < .05), except the 5 μg/mL triple group (P = .13). Expression of DJ-1, REDD1, and α-synuclein decreased numerically relative to Control without statistical significance (P > .05). Total-lysate cytochrome c was significantly elevated only in the triple-combination group compared with the Control group (mean [SEM], 36.01 [3.65] versus 22.63 [1.08] ng/mL; P = .03). Conclusions: Postinjury agmatine rescued 6-OHDA-induced viability loss, but sequential MitoTr followed by agmatine caused an additional marked reduction in viability rather than synergistic neuroprotection. Molecular alterations remained exploratory and nonsignificant. This MitoTr-associated loss may reflect antiproliferative effects in neuroblastoma-derived cells, underscoring the need for optimized protocols and nonmalignant models.
- Open Access
- 10 July 2026
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 19 (3) , 591-598
Possible new biomarkers to predict the recurrence and ophthalmopathy in patients with graves'
Purpose: Graves' disease (GD) is an antibody-mediated autoimmune thyroid disease characterized by hyperthyroidism and diffuse goiter. This study aimed to investigate the efficiency of novel biomarkers in the follow-up of Graves' disease (GD) by focusing on the expression of selected microRNAs (miRNAs).Materials and methods: Patients who were diagnosed with GD were included in this study. Expression levels of selected miRNAs were measured in both patients with GD (Group 1) and healthy controls (Group 2) by the real-time PCR method. The levels were compared between these two groups. The presence of ophthalmopathy and relapse was assessed and any effect of miRNA expression levels on those clinical parameters was evaluated.Results: There were 30 patients in each group. There was no significant difference between the groups in terms of the expression levels of selected miRNAs. However, there was a significant difference between the miR-154 expression levels of the patients with and without relapse (p=0.035).Conclusion: As per these results, miR-154 can be considered a predictor of disease relapse in the setting of GD. Further studies including larger newly diagnosed and untreated GD patient populations are needed to support this hypothesis.
- 10 July 2026
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 19 (3) , 591-598
Open AccessPossible new biomarkers to predict the recurrence and ophthalmopathy in patients with graves'
Purpose: Graves' disease (GD) is an antibody-mediated autoimmune thyroid disease characterized by hyperthyroidism and diffuse goiter. This study aimed to investigate the efficiency of novel biomarkers in the follow-up of Graves' disease (GD) by focusing on the expression of selected microRNAs (miRNAs).Materials and methods: Patients who were diagnosed with GD were included in this study. Expression levels of selected miRNAs were measured in both patients with GD (Group 1) and healthy controls (Group 2) by the real-time PCR method. The levels were compared between these two groups. The presence of ophthalmopathy and relapse was assessed and any effect of miRNA expression levels on those clinical parameters was evaluated.Results: There were 30 patients in each group. There was no significant difference between the groups in terms of the expression levels of selected miRNAs. However, there was a significant difference between the miR-154 expression levels of the patients with and without relapse (p=0.035).Conclusion: As per these results, miR-154 can be considered a predictor of disease relapse in the setting of GD. Further studies including larger newly diagnosed and untreated GD patient populations are needed to support this hypothesis.
- Open Access
- 10 July 2026
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 19 (3) , 81-88
Effect of various doses of metformin on map-kinase and apoptosis in penicillin-induced secondary rat cortical astrocytes-can metformin be antiepileptic?
Purpose: Astrocytes in the brain and spinal cord perform many functions and it express plasma membrane carriers for various neurotransmitters. Often sclerotic areas in the hippocampus are known as the cause of epilepsy. In reality, astrocytes initiate glutamate release in sclerotic tissue. In experimental epilepsy, penicillin is widely used to initiate this neuronal stress and establish the epilepsy model. The aim of this study is to demonstrate the protective effect of metformin, which has been proven to be effective in neurodegenerative diseases, on penicillin-induced astrocyte degeneration on the primary astrocyte cell line. This study is thought of as the first study about the effect of metformin on penicillin-induced astrocyte death.Materials and methods: For this purpose, secondary astrocyte cell culture which was previously obtained from the newborn rat brain was used.Results: The viability of penicillin-induced astrocyte cells was statistically significantly decreased (p=0.01), While cell viability increased statistically significantly in the metformin group at all metformin doses (p=0.01).Conclusions: We conclude that metformin has protective effects on damage caused by the penicillin secondary astrocyte cell line. These results suggest that penicillin reduces astrocyte cell viability, but metformin protects astrocytes against the lethal effect of penicillin.
- 10 July 2026
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 19 (3) , 81-88
Open AccessEffect of various doses of metformin on map-kinase and apoptosis in penicillin-induced secondary rat cortical astrocytes-can metformin be antiepileptic?
Purpose: Astrocytes in the brain and spinal cord perform many functions and it express plasma membrane carriers for various neurotransmitters. Often sclerotic areas in the hippocampus are known as the cause of epilepsy. In reality, astrocytes initiate glutamate release in sclerotic tissue. In experimental epilepsy, penicillin is widely used to initiate this neuronal stress and establish the epilepsy model. The aim of this study is to demonstrate the protective effect of metformin, which has been proven to be effective in neurodegenerative diseases, on penicillin-induced astrocyte degeneration on the primary astrocyte cell line. This study is thought of as the first study about the effect of metformin on penicillin-induced astrocyte death.Materials and methods: For this purpose, secondary astrocyte cell culture which was previously obtained from the newborn rat brain was used.Results: The viability of penicillin-induced astrocyte cells was statistically significantly decreased (p=0.01), While cell viability increased statistically significantly in the metformin group at all metformin doses (p=0.01).Conclusions: We conclude that metformin has protective effects on damage caused by the penicillin secondary astrocyte cell line. These results suggest that penicillin reduces astrocyte cell viability, but metformin protects astrocytes against the lethal effect of penicillin.
- 31 December 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 32
S-Sulfocysteine’s toxic effects on HT-22 cells are not triggered by glutamate receptors, nor do they involve apoptotic or genotoxicity mechanisms
S-Sulfocysteine (SSC) is a metabolite derived from the metabolism of sulfur-containing amino acids. It has been implicated in neurotoxicity observed in children with sulfite oxidase deficiency. The aim of our study was to confirm the neurotoxic effects of SSC using a mouse hippocampal cell line (HT-22) and to investigate the role of apoptosis in these effects, especially in terms of caspase-3 activation and genotoxicity. Based on the viability graph obtained following increasing concentrations of SSC, we determined the LC50 dose of SSC to be 125 µM by probit analysis. The cytotoxic effects of SSC were not reversed by glutamate receptor blocker administration. However, SSC treatment did not induce caspase-3 activation or induce DNA damage. Our results showed that SSC has a cytotoxic effect on neurons like glutamate, but glutamate receptor blockers reversed glutamate-induced toxicity, while these blockers did not protect neurons from SSC toxicity. The absence of caspase-3 activation and DNA fragmentation, which are indicative of apoptosis, in SSC-induced cell death suggests that alternative cell death pathways, such as necrosis and oxytosis may be implicated. Further research is necessary to fully elucidate SSC-induced cell death. The aim of our study was to confirm the neurotoxic effects of SSC using a mouse hippocampal cell line (HT-22) and to investigate the role of apoptosis in these effects, especially in terms of caspase-3 activation and genotoxicity.
- 31 December 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 32
S-Sulfocysteine’s toxic effects on HT-22 cells are not triggered by glutamate receptors, nor do they involve apoptotic or genotoxicity mechanisms
S-Sulfocysteine (SSC) is a metabolite derived from the metabolism of sulfur-containing amino acids. It has been implicated in neurotoxicity observed in children with sulfite oxidase deficiency. The aim of our study was to confirm the neurotoxic effects of SSC using a mouse hippocampal cell line (HT-22) and to investigate the role of apoptosis in these effects, especially in terms of caspase-3 activation and genotoxicity. Based on the viability graph obtained following increasing concentrations of SSC, we determined the LC50 dose of SSC to be 125 µM by probit analysis. The cytotoxic effects of SSC were not reversed by glutamate receptor blocker administration. However, SSC treatment did not induce caspase-3 activation or induce DNA damage. Our results showed that SSC has a cytotoxic effect on neurons like glutamate, but glutamate receptor blockers reversed glutamate-induced toxicity, while these blockers did not protect neurons from SSC toxicity. The absence of caspase-3 activation and DNA fragmentation, which are indicative of apoptosis, in SSC-induced cell death suggests that alternative cell death pathways, such as necrosis and oxytosis may be implicated. Further research is necessary to fully elucidate SSC-induced cell death. The aim of our study was to confirm the neurotoxic effects of SSC using a mouse hippocampal cell line (HT-22) and to investigate the role of apoptosis in these effects, especially in terms of caspase-3 activation and genotoxicity.
- Open Access
- 16 October 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Cisplatin Impact on Kasumi-1 Leukemia: Gene Expression and DNA Damage
Purpose: Leukemia is a type of cancer caused by the uncontrolled proliferation of blood cells. The purpose of this study was to investigate the effects of cisplatin (CIS), a chemotherapeutic agent used in the treatment of leukemia, on the Kasumi-1 leukemia cell line. Materials and methods: The study measured the effect of CIS on Kasumi-1 cells by calculating IC50 values for cell viability. The mRNA expression levels of apoptosis and cell cycle-related genes were then assessed using Real-Time PCR. In addition, the effects of CIS on DNA damage were investigated using the comet assay. Results: Significant changes in apoptosis and cell cycle-related genes were observed in CIS-treated groups. These included alterations in the mRNA levels of p53, BCL-2, CHECK 1, CDC25C, CDK 6, URG4/URGCP, GADD45A, CCND1, GADD45G, and ATM genes. Comet analysis confirmed CIS's effects on DNA damage. Conclusion: This study aimed to better understand how CIS affects genetic mechanisms in leukemia cells and provide new insights into leukemia treatment. The findings will help us better understand the role of CIS in leukemia treatment and will serve as a valuable reference for future research.
- 16 October 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Open AccessCisplatin Impact on Kasumi-1 Leukemia: Gene Expression and DNA Damage
Purpose: Leukemia is a type of cancer caused by the uncontrolled proliferation of blood cells. The purpose of this study was to investigate the effects of cisplatin (CIS), a chemotherapeutic agent used in the treatment of leukemia, on the Kasumi-1 leukemia cell line. Materials and methods: The study measured the effect of CIS on Kasumi-1 cells by calculating IC50 values for cell viability. The mRNA expression levels of apoptosis and cell cycle-related genes were then assessed using Real-Time PCR. In addition, the effects of CIS on DNA damage were investigated using the comet assay. Results: Significant changes in apoptosis and cell cycle-related genes were observed in CIS-treated groups. These included alterations in the mRNA levels of p53, BCL-2, CHECK 1, CDC25C, CDK 6, URG4/URGCP, GADD45A, CCND1, GADD45G, and ATM genes. Comet analysis confirmed CIS's effects on DNA damage. Conclusion: This study aimed to better understand how CIS affects genetic mechanisms in leukemia cells and provide new insights into leukemia treatment. The findings will help us better understand the role of CIS in leukemia treatment and will serve as a valuable reference for future research.
- Open Access
- 24 May 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Investigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells
Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.
- 24 May 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Open AccessInvestigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells
Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.
- Open Access
- 26 December 2023
- Published by Pamukkale University in Pamukkale Medical Journal
Potential effects of parietin on apoptosis and cell cycle related genes in SH-SY5Y neuroblastoma cells
Background: Ingredients obtained from natural products have been used in cancer treatments for years. High diversity and non-toxicity compared to chemotherapeutic agents are the main reasons for their preference. Lichens having potential for treatment of cancer consist of fungus and 1-2 species of algae. Under the name of lichen substances, many of them have also been synthesized as specific substances. The secondary metabolites in lichens are generally insoluble in water, and have many biological activities such as antiviral, antitumor, antibacterial, and antioxidant; they store in the fungal cell or on the surface of the hyphae and can only be extracted with organic solvents. Parietin extracted from lichen species such as xanthoria parietina is an anthraquinone pigment and a secondary metabolite. In our study, the effects of parietin on cytotoxicity, gene expression, migration, invasion, and colony formation in neuroblastoma cells treated with parietin were investigated. The SH-SY5Y neuroblastoma (NB), which is not treated with parietin, was administered as a control group. Methods: The IC50 value of the parietin was determined using XTT assay. The total RNA extractions were performed from the cells using the Tri-Reagent kit. The expressions of BCL-XL, BCL-2, MMP2, MMP9, P21, CYCLIN D1, CASAPASE-3, CASAPASE-9, BAX, P53, PUMA, and NOXA genes were investigated by Lightcycler 480 (Roche) using SYBR Green dye. Migration analysis of the control and the dose group cells were performed in accordance with the Wound-healing assay protocol. Invasion activities were determined using the “Invasion Chamber” (BD Biosciences) protocol. The colony assay was treated with crystal violet and the cells were observed under the light microscope. Results: The IC50 value of the parietin used for 48-hour treatment on the cells was determined as 35 µM. It was found that the expression levels of BCL-XL, BCL-2, MMP2, MMP9, P21, and CYCLIN D1 mRNA were downregulated, and it was also shown the expression levels of CASAPASE-3, CASAPASE-9, BAX, P53, PUMA, and NOXA to be upregulated. It was determined that parietin suppressed both cell invasion and migration, and colony formation in the neuroblastoma cells. Conclusions: Thus, it can be possible parietin to be used as an alternative, complementary, and supportive agent together with the other drugs in the treatment of neuroblastoma. However, more comprehensive studies supporting these significant effects of parietin will increase its potential in the application.
- 26 December 2023
- Published by Pamukkale University in Pamukkale Medical Journal
Open AccessPotential effects of parietin on apoptosis and cell cycle related genes in SH-SY5Y neuroblastoma cells
Background: Ingredients obtained from natural products have been used in cancer treatments for years. High diversity and non-toxicity compared to chemotherapeutic agents are the main reasons for their preference. Lichens having potential for treatment of cancer consist of fungus and 1-2 species of algae. Under the name of lichen substances, many of them have also been synthesized as specific substances. The secondary metabolites in lichens are generally insoluble in water, and have many biological activities such as antiviral, antitumor, antibacterial, and antioxidant; they store in the fungal cell or on the surface of the hyphae and can only be extracted with organic solvents. Parietin extracted from lichen species such as xanthoria parietina is an anthraquinone pigment and a secondary metabolite. In our study, the effects of parietin on cytotoxicity, gene expression, migration, invasion, and colony formation in neuroblastoma cells treated with parietin were investigated. The SH-SY5Y neuroblastoma (NB), which is not treated with parietin, was administered as a control group. Methods: The IC50 value of the parietin was determined using XTT assay. The total RNA extractions were performed from the cells using the Tri-Reagent kit. The expressions of BCL-XL, BCL-2, MMP2, MMP9, P21, CYCLIN D1, CASAPASE-3, CASAPASE-9, BAX, P53, PUMA, and NOXA genes were investigated by Lightcycler 480 (Roche) using SYBR Green dye. Migration analysis of the control and the dose group cells were performed in accordance with the Wound-healing assay protocol. Invasion activities were determined using the “Invasion Chamber” (BD Biosciences) protocol. The colony assay was treated with crystal violet and the cells were observed under the light microscope. Results: The IC50 value of the parietin used for 48-hour treatment on the cells was determined as 35 µM. It was found that the expression levels of BCL-XL, BCL-2, MMP2, MMP9, P21, and CYCLIN D1 mRNA were downregulated, and it was also shown the expression levels of CASAPASE-3, CASAPASE-9, BAX, P53, PUMA, and NOXA to be upregulated. It was determined that parietin suppressed both cell invasion and migration, and colony formation in the neuroblastoma cells. Conclusions: Thus, it can be possible parietin to be used as an alternative, complementary, and supportive agent together with the other drugs in the treatment of neuroblastoma. However, more comprehensive studies supporting these significant effects of parietin will increase its potential in the application.
- 1 June 2023
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Investigation of Toll-Like Receptor Family Expression in Glioblastoma: A Comparative Analysis of qPCR and Cell Culture
Amaç: Glioblastoma yetişkinlerde en sık görülen ölümcül beyin kanseridir. Toll-benzeri reseptörler, patojen tanıma ve doğal bağışıklığın aktivasyonu ile ilişkili 10 reseptörden (Toll-benzeri reseptör 1-10) oluşan hücre yüzey reseptörleridir. Ancak, çelişkili sonuçlar içermekle birlikte bazı çalışmalar Toll benzeri reseptör ekspresyonunun, glioblastoma dahil bazı tümörlerde, kanser hücresi proliferasyonu ve ilerlemesi ile ilişkili olabileceğini göstermiştir. Bu nedenle, bu çalışmada literatürde ilk kez glioblastomada Toll- benzeri reseptörlerin on üyesinin tamamının ekspresyon profilinin araştırılması amaçlandı. Hastalar ve Yöntem: 2018 yılı Ocak ve Aralık ayları arasında tanı alan 25 glioblastoma hastasına ait formalinle fikse edilmiş parafine gömülmüş dokularda Toll-benzeri reseptörlerin mRNA ekspresyonu kantitatif gerçek zamanlı polimeraz zincir reaksiyonu kullanılarak değerlendirildi. Ayrıca her bir Toll- benzeri reseptörün ekspresyonu, beş farklı insan glioblastom hücre hattı (T98G, U87-MG, U373, LN18 ve A172) kullanılarak hücre kültürü analizi ile araştırıldı. Bulgular: Glioblastoma grubunun formalinle fikse edilmiş parafine gömülmüş dokularında kantitatif gerçek zamanlı polimeraz zincir reaksiyonu analizi ile Toll-benzeri reseptör 1, Toll-benzeri reseptör 6 ve Toll-benzeri reseptör 7 mRNA düzeyleri anlamlı olarak arttığı (her biri, p<0.001), Toll-benzeri reseptör 4 ve Toll-benzeri reseptör 10 düzeylerinin ise kontrol grubu ile kıyaslandığında anlamlı olarak azaldığı görüldü (sırası ile, p=0.023, p<0.001). Ek olarak, Toll-benzeri reseptör mRNA ekspresyon profilleri farklı hücre hatları arasında farklılık sergiledi. Sonuç: Çalışmamızda birçok Toll-benzeri reseptör üyesi glioblastoma mikroçevresinde farklı ekspresyon düzeyi gösteriyor ve onu farklı şekilde etkiliyor gibi görünüyordu. Glioblastomada her bir Toll-benzeri reseptörün endojen protein seviyesini doğrulamak, glioblastomanın patogenezi ve prognozu üzerindeki kesin rollerini netleştirmek ve yeni hedef tedavilere ışık tutmak için daha kapsamlı çalışmalara ihtiyaç duyulmaktadır.
- 1 June 2023
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Investigation of Toll-Like Receptor Family Expression in Glioblastoma: A Comparative Analysis of qPCR and Cell Culture
Amaç: Glioblastoma yetişkinlerde en sık görülen ölümcül beyin kanseridir. Toll-benzeri reseptörler, patojen tanıma ve doğal bağışıklığın aktivasyonu ile ilişkili 10 reseptörden (Toll-benzeri reseptör 1-10) oluşan hücre yüzey reseptörleridir. Ancak, çelişkili sonuçlar içermekle birlikte bazı çalışmalar Toll benzeri reseptör ekspresyonunun, glioblastoma dahil bazı tümörlerde, kanser hücresi proliferasyonu ve ilerlemesi ile ilişkili olabileceğini göstermiştir. Bu nedenle, bu çalışmada literatürde ilk kez glioblastomada Toll- benzeri reseptörlerin on üyesinin tamamının ekspresyon profilinin araştırılması amaçlandı. Hastalar ve Yöntem: 2018 yılı Ocak ve Aralık ayları arasında tanı alan 25 glioblastoma hastasına ait formalinle fikse edilmiş parafine gömülmüş dokularda Toll-benzeri reseptörlerin mRNA ekspresyonu kantitatif gerçek zamanlı polimeraz zincir reaksiyonu kullanılarak değerlendirildi. Ayrıca her bir Toll- benzeri reseptörün ekspresyonu, beş farklı insan glioblastom hücre hattı (T98G, U87-MG, U373, LN18 ve A172) kullanılarak hücre kültürü analizi ile araştırıldı. Bulgular: Glioblastoma grubunun formalinle fikse edilmiş parafine gömülmüş dokularında kantitatif gerçek zamanlı polimeraz zincir reaksiyonu analizi ile Toll-benzeri reseptör 1, Toll-benzeri reseptör 6 ve Toll-benzeri reseptör 7 mRNA düzeyleri anlamlı olarak arttığı (her biri, p<0.001), Toll-benzeri reseptör 4 ve Toll-benzeri reseptör 10 düzeylerinin ise kontrol grubu ile kıyaslandığında anlamlı olarak azaldığı görüldü (sırası ile, p=0.023, p<0.001). Ek olarak, Toll-benzeri reseptör mRNA ekspresyon profilleri farklı hücre hatları arasında farklılık sergiledi. Sonuç: Çalışmamızda birçok Toll-benzeri reseptör üyesi glioblastoma mikroçevresinde farklı ekspresyon düzeyi gösteriyor ve onu farklı şekilde etkiliyor gibi görünüyordu. Glioblastomada her bir Toll-benzeri reseptörün endojen protein seviyesini doğrulamak, glioblastomanın patogenezi ve prognozu üzerindeki kesin rollerini netleştirmek ve yeni hedef tedavilere ışık tutmak için daha kapsamlı çalışmalara ihtiyaç duyulmaktadır.
- 1 August 2021
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 47 (2) , 219-223
Erianinin HT29 Kolorektal Kanser Hücrelerinin Proliferasyonu ve Koloni Oluşumu Üzerine Etkilerinin Araştırılması
Kolorektal kanser, dünyada kanser ilişkili ölümlerin en yaygın dördüncü sebebidir. Erianin antioksidan ve anti-tümör etkilere sahip Dendrobium ekstraktından elde edilen yeni bir dibenzil bileşiğidir. Bu çalışmada, erianinin HT29 kolorektal kanser hücreleri üzerine olan terapötik etkileri araştırılmıştır. Erianinin HT29 hücre canlılığı üzerine etkileri XTT test ile koloni oluşumu üzerine etkileri ise koloni formasyonu ile değerlendirilmiştir. Erianinin HT29 hücrelerinde IC50 değeri 48. saatte 59.05 μM olarak belirlenmiştir. HT29 hücre dizisinde erianin uygulanan grupta koloni sayısı 67±33 iken kontrol grubunda 350±89 olarak hesaplanmıştır. Erianin, HT29 kolorektal kanser hücrelerinde koloni oluşumunu ise anlamlı derecede azaltmıştır. Yapılan çalışmaların sonuçları, erianinin kolorektal kanser tedavisinde doğal elde edilen bir bileşik olarak güvenli, kolay ulaşılabilir ve umut veren terapötik bir ilaç olabileceğini destekler niteliktedir. Gelecekte erianinin kolorektal kanser hücreleri üzerindeki etki mekanizmasını aydınlatacak daha kapsamlı ve çok merkezli desteklenecek ileri düzeyde klinik çalışmalara ihtiyaç vardır.
- 1 August 2021
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 47 (2) , 219-223
Erianinin HT29 Kolorektal Kanser Hücrelerinin Proliferasyonu ve Koloni Oluşumu Üzerine Etkilerinin Araştırılması
Kolorektal kanser, dünyada kanser ilişkili ölümlerin en yaygın dördüncü sebebidir. Erianin antioksidan ve anti-tümör etkilere sahip Dendrobium ekstraktından elde edilen yeni bir dibenzil bileşiğidir. Bu çalışmada, erianinin HT29 kolorektal kanser hücreleri üzerine olan terapötik etkileri araştırılmıştır. Erianinin HT29 hücre canlılığı üzerine etkileri XTT test ile koloni oluşumu üzerine etkileri ise koloni formasyonu ile değerlendirilmiştir. Erianinin HT29 hücrelerinde IC50 değeri 48. saatte 59.05 μM olarak belirlenmiştir. HT29 hücre dizisinde erianin uygulanan grupta koloni sayısı 67±33 iken kontrol grubunda 350±89 olarak hesaplanmıştır. Erianin, HT29 kolorektal kanser hücrelerinde koloni oluşumunu ise anlamlı derecede azaltmıştır. Yapılan çalışmaların sonuçları, erianinin kolorektal kanser tedavisinde doğal elde edilen bir bileşik olarak güvenli, kolay ulaşılabilir ve umut veren terapötik bir ilaç olabileceğini destekler niteliktedir. Gelecekte erianinin kolorektal kanser hücreleri üzerindeki etki mekanizmasını aydınlatacak daha kapsamlı ve çok merkezli desteklenecek ileri düzeyde klinik çalışmalara ihtiyaç vardır.
- Open Access
- 11 May 2021
- Published by Academician Publishing
Hepatoloji
Karaciğer Anatomisi Gülay Açar Karaciğer Histolojisi ve Embriyolojisi Gülsemin Çiçek Emine Utlu Özen Karaciğer Hastalıklarının Patolojisi Ruksan Çopuroğlu Buket Gedik Karaciğerin Benign Kitlelerinin Patolojisi Ganime Çoban Yeliz Arman Karakaya Karaciğer Prekürsör Lezyonlarının ve Malign Tümörlerinin Patolojisi Döndü Nergiz Hülya Tosun Yıldırım Karaciğerin Hücresel Hasarı ve Fibrozis Yeliz ARMAN KARAKAYA Şirin KÜÇÜK Harun KÜÇÜK Karaciğer Fizyolojisi Ve Hücresel Fonksiyonları Güven GÜVENDİ Saime ÖZBEK ŞEBİN Safra Oluşumu Ve Fizyolojisi Metin Yalaza Yavuz Çağır İntestinal Flora Ve Karaciğer Hastalıkları -1 Murat Deveci Hafize Kızılkaya İntestinal Flora Ve Karaciğer Hastalıkları - 2 Esma Eroğlu Arzu Tarakçı Karaciğer ve İmmünite Gökçe Kundakçı Gelir Berrin Yalınbaş Kaya Hepatosellüler Karsinomun Moleküler Mekanizmaları Levent Elmas Mücahit Seçme Hepatosit Transplantasyonu Ve Kök Hücre Gülsemin Çiçek Karaciğer Ve Sirkadiyen Ritim Volkan TEKİN Karaciğer Fonksiyon Testleri Ve Güncel Gelişmeler Türkan Güney Ali Karataş Sarılıkta Patofizyoloji Ve Klinik Değerlendirme Tuba Erürker Öztürk Gebelik ve Karaciğer Özlem Koşar Can Batuhan Başpınar Karacı̇ğer ve Beslenmeye Klı̇nı̇k ve Moleküler Açıdan Yaklaşım Hatice Hamarat Özge Alkan Tali Karaciğer Hastalıklarında Girişimsel Endoskopik Yöntemler Mehmet Alpua Karaciğer Hastalıklarında Görüntüleme Mustafa Devran Aybar Karaciğerin Benign ve Malign Hastalıklarında Görüntüleme Mahmut ÇORAPLI Kamil DOĞAN Karaciğer Tümörlerinde Girişimsel Yöntemlere Cerrahi Bakış Sait Tayfun Karaciğer Hastalıkları Ve Girişimsel Radyoloji Seda Nida Karaküçük Karaciğer Tümörleri Ve Girişimsel Radyoloji Muhammet ARSLAN Halil Serdar ASLAN Karaciğer Kitlelerinde Tanı Ve Semptomatoloji Yonca Yılmaz Ürün Ferhat Bacaksız Karaciğerin Benign Kitleleri Murat Pekgöz Sevil Özer Sarı Karaciğerin Malign Kitleleri Mustafa Gürkan Haytaoğlu Karaciğerin Malign Kitlelerinde Medikal Onkoloji Ve Tedavi Rejimleri Sabri Güncan Kronik Karaciğer Hastalıklarının Etiyolojisi ve Klinik Yaklaşım Barış Soydaş Viral Hepatitler İle İlgili Genel Bilgiler Sercan Kiremitçi Hepatit B Ve D Enfeksiyonlarına Yaklaşım ve Tedavi Berk Baş Ramazan Gözüküçük Hepatit C’ye Yaklaşım ve Tedavi Zuhal Yeşilbağ Murat Pekgöz Hepatit A Virüs Enfeksiyonu Esma Kepenek Kurt Mevlüt Kıyak Hepatit E Virüs Enfeksiyonu ve Klinik Yaklaşım Esma EROĞLU Mesut GÜMÜŞSOY Sistemik Viral Enfeksiyonlar ve Karaciğer Şaban İNCECİK Vedat KILIÇ Alkolik Hepatit Rahmi ASLAN Yaren DİRİK Non-Alkolik Yağlı Karaciğer Hastalığı Tanı ve Tedavi Yaklaşımı Yakup ÜLGER Derya ARI Otoimmün Hepatit Tanı Ve Tedavisi Yavuz ÇAĞIR Primer Biliyer Kolanjit, Sekonder Biliyer Siroz, Primer Sklerozan Kolanjit, Sekonder Sklerozan Kolanjit Çağdaş Erdoğan Mehmet Köroğlu Budd-Chiari Sendromu Ve Venookluziv Hastalıkta Tanı Ve Tedavi Fatih EREN Berrin YALINBAŞ KAYA İlaç İlişkili Karaciğer Yetmezliği: Etkenler, Tanı Ve Tedavi Filiz ARAZ Akut Karaciğer Yetmezliği Murat İSPİROĞLU Mesut AYDIN Kronik Karaciğer Hastalıklarında Akut Alevlenmeler ve Yaklaşım Mustafa AKAR Çınar YILDIRIM Siroz Tedavisinde Kullanılan Başlıca İlaçlar Elif Tuğba TUNCEL Karaciğer Sirozu Ve Dekompansasyon Bilal TOKA Salih TOKMAK Karaciğer Sirozu Ve Tüm Yönleriyle Laboratuvar Değerlendirme Berat EBİK Hüseyin KAÇMAZ Portal Hipertansiyon Kübra AKAN Portal Hipertansiyona Cerrahi Yaklaşım Ufuk ARSLAN Portal Ven ve Splenik Ven Trombozuna Klinik ve Cerrahi Yaklaşım Fatih KIVRAKOĞLU Murat GÜNER M.Fevzi CELAYİR Karaciğer Hastalıklarında Anamnez Ve Fizik Muayene Mehmet KÖROĞLU Karacığer Hastalıkları Ve Nörolojık Bulgular Güven ARSLAN Hepatorenal Sendrom Murat DEVECİ Vedat GENÇER Hepatopulmoner Sendrom, Portopulmoner Hipertansiyon Çağdaş Erdoğan Mehmet Fatih Elverişli Karaciğer Hastalıkları Ve Hematopoietik Sistem, Hemostaz Funda Pepedil Tanrıkulu Filiz Araz Karaciğerin Paraziter Hastalıkları Ve Medikal Tedavi Safiye Koçulu Demir Karaciğerin Paraziter Hastalıklarında Cerrahi Tedavi Özhan Albayrak Ali Sürmelioğlu Karaciğerin Bakteriyel ve Mantar Enfeksiyonları ve Apselerine Medikal Yaklaşım Suzan Şahin Nazım Ekin Karaciğerin Bakteriyel Ve Mantar Enfeksiyonlarına Ve Apselerine Cerrahi Yaklaşım Sami Benli Dursun Burak Özdemir Karaciğer Nakli Öncesi Hasta Ve Donör Hazırlığı Şencan Acar Karaciğer Naklinde Endikasyon ve Kontrendikasyonlar Muhammed Raşid Aykota Şencan Acar Karaciğer Nakli...
- 11 May 2021
- Published by Academician Publishing
Open AccessHepatoloji
Karaciğer Anatomisi Gülay Açar Karaciğer Histolojisi ve Embriyolojisi Gülsemin Çiçek Emine Utlu Özen Karaciğer Hastalıklarının Patolojisi Ruksan Çopuroğlu Buket Gedik Karaciğerin Benign Kitlelerinin Patolojisi Ganime Çoban Yeliz Arman Karakaya Karaciğer Prekürsör Lezyonlarının ve Malign Tümörlerinin Patolojisi Döndü Nergiz Hülya Tosun Yıldırım Karaciğerin Hücresel Hasarı ve Fibrozis Yeliz ARMAN KARAKAYA Şirin KÜÇÜK Harun KÜÇÜK Karaciğer Fizyolojisi Ve Hücresel Fonksiyonları Güven GÜVENDİ Saime ÖZBEK ŞEBİN Safra Oluşumu Ve Fizyolojisi Metin Yalaza Yavuz Çağır İntestinal Flora Ve Karaciğer Hastalıkları -1 Murat Deveci Hafize Kızılkaya İntestinal Flora Ve Karaciğer Hastalıkları - 2 Esma Eroğlu Arzu Tarakçı Karaciğer ve İmmünite Gökçe Kundakçı Gelir Berrin Yalınbaş Kaya Hepatosellüler Karsinomun Moleküler Mekanizmaları Levent Elmas Mücahit Seçme Hepatosit Transplantasyonu Ve Kök Hücre Gülsemin Çiçek Karaciğer Ve Sirkadiyen Ritim Volkan TEKİN Karaciğer Fonksiyon Testleri Ve Güncel Gelişmeler Türkan Güney Ali Karataş Sarılıkta Patofizyoloji Ve Klinik Değerlendirme Tuba Erürker Öztürk Gebelik ve Karaciğer Özlem Koşar Can Batuhan Başpınar Karacı̇ğer ve Beslenmeye Klı̇nı̇k ve Moleküler Açıdan Yaklaşım Hatice Hamarat Özge Alkan Tali Karaciğer Hastalıklarında Girişimsel Endoskopik Yöntemler Mehmet Alpua Karaciğer Hastalıklarında Görüntüleme Mustafa Devran Aybar Karaciğerin Benign ve Malign Hastalıklarında Görüntüleme Mahmut ÇORAPLI Kamil DOĞAN Karaciğer Tümörlerinde Girişimsel Yöntemlere Cerrahi Bakış Sait Tayfun Karaciğer Hastalıkları Ve Girişimsel Radyoloji Seda Nida Karaküçük Karaciğer Tümörleri Ve Girişimsel Radyoloji Muhammet ARSLAN Halil Serdar ASLAN Karaciğer Kitlelerinde Tanı Ve Semptomatoloji Yonca Yılmaz Ürün Ferhat Bacaksız Karaciğerin Benign Kitleleri Murat Pekgöz Sevil Özer Sarı Karaciğerin Malign Kitleleri Mustafa Gürkan Haytaoğlu Karaciğerin Malign Kitlelerinde Medikal Onkoloji Ve Tedavi Rejimleri Sabri Güncan Kronik Karaciğer Hastalıklarının Etiyolojisi ve Klinik Yaklaşım Barış Soydaş Viral Hepatitler İle İlgili Genel Bilgiler Sercan Kiremitçi Hepatit B Ve D Enfeksiyonlarına Yaklaşım ve Tedavi Berk Baş Ramazan Gözüküçük Hepatit C’ye Yaklaşım ve Tedavi Zuhal Yeşilbağ Murat Pekgöz Hepatit A Virüs Enfeksiyonu Esma Kepenek Kurt Mevlüt Kıyak Hepatit E Virüs Enfeksiyonu ve Klinik Yaklaşım Esma EROĞLU Mesut GÜMÜŞSOY Sistemik Viral Enfeksiyonlar ve Karaciğer Şaban İNCECİK Vedat KILIÇ Alkolik Hepatit Rahmi ASLAN Yaren DİRİK Non-Alkolik Yağlı Karaciğer Hastalığı Tanı ve Tedavi Yaklaşımı Yakup ÜLGER Derya ARI Otoimmün Hepatit Tanı Ve Tedavisi Yavuz ÇAĞIR Primer Biliyer Kolanjit, Sekonder Biliyer Siroz, Primer Sklerozan Kolanjit, Sekonder Sklerozan Kolanjit Çağdaş Erdoğan Mehmet Köroğlu Budd-Chiari Sendromu Ve Venookluziv Hastalıkta Tanı Ve Tedavi Fatih EREN Berrin YALINBAŞ KAYA İlaç İlişkili Karaciğer Yetmezliği: Etkenler, Tanı Ve Tedavi Filiz ARAZ Akut Karaciğer Yetmezliği Murat İSPİROĞLU Mesut AYDIN Kronik Karaciğer Hastalıklarında Akut Alevlenmeler ve Yaklaşım Mustafa AKAR Çınar YILDIRIM Siroz Tedavisinde Kullanılan Başlıca İlaçlar Elif Tuğba TUNCEL Karaciğer Sirozu Ve Dekompansasyon Bilal TOKA Salih TOKMAK Karaciğer Sirozu Ve Tüm Yönleriyle Laboratuvar Değerlendirme Berat EBİK Hüseyin KAÇMAZ Portal Hipertansiyon Kübra AKAN Portal Hipertansiyona Cerrahi Yaklaşım Ufuk ARSLAN Portal Ven ve Splenik Ven Trombozuna Klinik ve Cerrahi Yaklaşım Fatih KIVRAKOĞLU Murat GÜNER M.Fevzi CELAYİR Karaciğer Hastalıklarında Anamnez Ve Fizik Muayene Mehmet KÖROĞLU Karacığer Hastalıkları Ve Nörolojık Bulgular Güven ARSLAN Hepatorenal Sendrom Murat DEVECİ Vedat GENÇER Hepatopulmoner Sendrom, Portopulmoner Hipertansiyon Çağdaş Erdoğan Mehmet Fatih Elverişli Karaciğer Hastalıkları Ve Hematopoietik Sistem, Hemostaz Funda Pepedil Tanrıkulu Filiz Araz Karaciğerin Paraziter Hastalıkları Ve Medikal Tedavi Safiye Koçulu Demir Karaciğerin Paraziter Hastalıklarında Cerrahi Tedavi Özhan Albayrak Ali Sürmelioğlu Karaciğerin Bakteriyel ve Mantar Enfeksiyonları ve Apselerine Medikal Yaklaşım Suzan Şahin Nazım Ekin Karaciğerin Bakteriyel Ve Mantar Enfeksiyonlarına Ve Apselerine Cerrahi Yaklaşım Sami Benli Dursun Burak Özdemir Karaciğer Nakli Öncesi Hasta Ve Donör Hazırlığı Şencan Acar Karaciğer Naklinde Endikasyon ve Kontrendikasyonlar Muhammed Raşid Aykota Şencan Acar Karaciğer Nakli...